Phosphoinositide 3-kinase (PI3K) is an important therapeutic target. Mutations in PIK3CA, which encodes p110a, the catalytic subunit of PI3K, occur in endometrioid endometrial cancers (EEC) and nonendometrioid endometrial cancers (NEEC). The goal of this study was to determine whether PIK3R1, which encodes p85a, the inhibitory subunit of PI3K, is mutated in endometrial carcinoma. We carried out exonic sequencing of PIK3R1 from 42 EECs and 66 NEECs. The pattern of PIK3R1 mutations was compared with the patterns of PIK3CA, PTEN, and KRAS mutations. The biochemical effect of seven PIK3R1 mutations was examined by stable expression in U2OS cells, followed by coimmunoprecipitation analysis of p110a, and Western blotting of phospho-AKT Ser473 (p-AKT Ser473 ). We found that PIK3R1 was somatically mutated in 43% of EECs and 12% of NEECs. The majority of mutations (93.3%) were localized to the p85a-nSH2 and -iSH2 domains. Several mutations were recurrent. PIK3R1 mutations were significantly (P ¼ 0.0015) more frequent in PIK3CA-wild type EECs (70%) than in PIK3CA mutant EECs (18%). Introduction of wild-type p85a into U2OS cells reduced the level of p-AKT Ser473 compared with the vector control. Five p85a mutants, p85adelH450-E451, p85adelK459, p85adelY463-L466, p85adelR574-T576, and the p85aN564D positive control, were shown to bind p110a and led to increased levels of p-AKT Ser473 .
Introduction
Endometrial cancer kills approximately 74,000 women worldwide each year (1) . Tumors are classified into 2 major subtypes, endometrioid endometrial cancers (EEC) and nonendometrioid endometrial cancers (NEEC; ref. 2) . At diagnosis, the vast majority of endometrial tumors are EECs. Although many EECs are detected at an early stage and can be treated effectively with surgery, improved therapeutic strategies are needed for the treatment of recurrent and advanced-stage EECs (3, 4) . NEECs represent a minority of tumors at presentation (4), but they are the most clinically aggressive subtype and cause a disproportionate fraction of all endometrial cancer-related deaths (5) . Therefore, new therapeutic approaches to treat NEEC are needed.
The phosphoinositide 3-kinase (PI3K) signal transduction pathway represents an important therapeutic target (6) . PI3K is a heterodimer composed of a catalytic subunit (p110a) encoded by PIK3CA and a regulatory subunit (p85a) encoded by PIK3R1. In quiescent cells, p85a binds to p110a and causes both stabilization and catalytic inhibition of p110a. Somatic mutations in PIK3CA occur in many tumor types, including endometrial cancer (7, 8) , whereas somatic PIK3R1 mutations are restricted to a few tumor types (9) (10) (11) (12) .
We recently showed that the ABD and C2 domains of p110a, which mediate binding to p85a, are frequently mutated in endometrial carcinomas (13) . We therefore hypothesized that PIK3R1 (p85a) itself might be mutated in endometrial tumors. Herein, we report that PIK3R1 is somatically mutated in 43% of EECs and 12% of NEECs. Mutations preferentially localized to the p85a-iSH2 domain, which mediates binding to p110a. Several PIK3R1 mutations promoted increased phosphorylation of AKT Ser473 . Collectively, our findings reveal a new mechanism by which the PI3K pathway is activated in endometrial cancer.
Materials and Methods

Clinical material
Primary tumor (42 EECs and 66 NEECs) and matched normal tissues were collected at resection, prior to treatment, and obtained with appropriate Institutional Review Board approval (13) . A pathologist reviewed hematoxylin and eosin sections of tumors to verify histology and delineate regions of tissue composed of more than 70% tumor cells for macrodissection.
Genomic DNA extraction and identity testing
Genomic DNA was isolated from macrodissected tumor tissue or normal tissue by using the PUREGENE Kit (Gentra Systems). Matched tumor and normal DNAs were genotyped using the Coriell Identity Testing Kit.
PCR and sequencing
All coding exons of PIK3R1 were amplified from tumor DNA, using the PCR, followed by nucleotide sequencing (see Supplementary Methods). Purified tumor cell populations were isolated from 3 tumors by using laser capture microdissection (LCM), followed by reverse transcriptase PCR (RT-PCR) and sequencing to determine whether there was monoallelic or biallelic expression of mutations (See Supplementary Methods).
Expression constructs
A retroviral expression construct containing full-length, wild-type PIK3R1 cDNA in the pBABE vector (Addgene) was used to generate a series of PIK3R1 mutant constructs by sitedirected mutagenesis with the QuikChange II XL Site-Directed Mutagenesis Kit (Stratagene). Inserts were excised using BamHI and SalI and subcloned into the MYC-tagged pCMV-3Tag-7 expression vector (Agilent Technologies). The integrity of inserts was confirmed by Sanger sequencing.
Transfections, immunoprecipitation, and Western blotting
The osteosarcoma cell line U2OS was provided by Sean Lee (NIH); it was not subjected to an authentication test. U2OS cells were transfected with vector, wild-type, or mutant p85a expression constructs by using FuGENE-6 (Roche). Following hygromycin selection, pools of stably selected cells were serum starved in DMEM/0.5% FBS for 16 hours, followed by lysis and Western blotting (details in Supplementary Methods). For immunoprecipitation, lysates were incubated with MYC-tag Sepharose bead conjugates (Cell Signaling) overnight at 4 C. All Western blots were repeated in triplicate. Tables S3 and S4 ).
Results
Somatic
The distribution of PIK3R1 mutations was nonrandom; 93.3% (28 of 30) of PIK3R1 mutations, including 3 recurrent mutations, localized to the nSH2 and iSH2 domains of p85a that mediate binding to p110a (Fig. 1) . Fifty percent (15 of 30) of all coding mutations localized within the proximal region (residues 434-475) of the iSH2 domain, including a series of 10 overlapping in-frame deletions defined by 3 shortest regions of overlap (SRO1-SRO3; Fig. 1 ).
All somatic PIK3R1 mutations seemed to be heterozygous. To determine whether the mutations were truly heterozygous or if the wild-type allele was contributed by contaminating normal cells, we used LCM to isolate purified tumor cell populations from 3 cases (T88, T100, and T120), followed by RT-PCR and sequencing. Expression of both mutant and wild-type alleles was observed, confirming heterozygosity in tumor cells ( Supplementary Fig. S2 ).
In EECs, PIK3R1 mutations frequently coexist with PTEN and KRAS mutations but tend to be mutually exclusive with PIK3CA mutations PIK3R1 and PIK3CA mutations are mutually exclusive in glioblastoma multiforme but coexist in colorectal cancer (10, 11, 14) . We previously determined the mutational status of PIK3CA, PTEN, and KRAS in our endometrial tumors (13) . When these results were merged with those from our analysis of PIK3R1 mutations, we found that 95% (40 of 42 cases) of EECs, and 41% (27 of 66) of NEECs had somatically mutated 1 or more of the 4 genes (Fig. 2) . We evaluated the patterns of mutations among EECs because all 4 genes were mutated at high frequency in these tumors. There was no significant difference in the frequency of PIK3R1 mutations between PTEN mutant (48%, 16 of 33 tumors) and PTEN wild-type EECs (22%, 2 of 9 tumors), or between KRAS mutant (50%, 9 of 18 tumors) and KRAS wild-type EECs (37%, 9 of 24 tumors). In contrast, PIK3R1 mutations were significantly (P ¼ 0.0015) more frequent in PIK3CA wild-type EECs (70%, 14 of 20) than in PIK3CA mutant EECs (18%, 4 of 22).
Ten tumors (4 EECs and 6 NEECs) had coexisting PIK3R1 and PIK3CA mutations (Table 2) . Strikingly, the proportion of truncating mutants of PIK3R1 that coexisted with PIK3CA mutants (63%, 7 of 11 truncations) was significantly higher (P ¼ 0.010) than the proportion of missense mutations or inframe insertions/deletions of PIK3R1 (12%, 2 of 17 mutations) that coexisted with PIK3CA mutations.
A subset of p85a mutants leads to increased phosphorylation of AKT Ser473 in vitro We transfected U2OS osteosarcoma cells with constructs expressing either wild-type or mutant PIK3R1 to determine the biochemical effects of p85a mutants on phosphorylation of AKT Ser473 , an important PI3K substrate. We used U2OS cells because they express low endogenous levels of phospho-AKT Ser473 (p-AKT
Ser473
; ref. 15) . Seven p85a mutants present in endometrial tumors were analyzed: p85adelK459 and p85adelY463-L466, which define SRO2 and SRO3; Table 1 . The predicted protein change was determined by sequencing RT-PCR products to determine any effect of the mutated intronic bases on splicing.
p85aR348X and p85adelR574-T576, which were recurrent mutations in our study; p85aK511VfsX2, the most carboxyterminal truncation mutant; and p85adelH450-E451 and p85aN564D, which were present in endometrial tumors as well as in other tumor types (10, 11) . p85aN564D served as a positive control because it is known to increase PI3K activity (10) . Coimmunoprecipitation of p110a and MYC-tagged p85a mutants showed that all mutants retained the ability to bind p110a except for p85aR348X and p85adelK511VfsX2 (Fig. 3A) . Western blotting showed the expected low endogenous level of p-AKT Ser473 in U2OS cells transfected with the vector control (Fig. 3B) . As noted previously (10) , and consistent with the inhibitory effect of wild-type p85a on the PI3K pathway, introduction of wild-type p85a into U2OS cells reduced the level of p-AKT Ser473 compared with vector alone (Fig. 3B) . In contrast to wild-type p85a, stable expression of 5 p85a mutants (p85adelH450-E451, p85adelK459, p85adelY463-L466, p85adelR574-T576, and p85aN564D) led to increased levels of p-AKT Ser473 compared with vector control (Fig. 3B) . Only the p85aR348X and p85aK511VfsX2 mutants did not exhibit appreciable changes in p-AKT Ser473 levels compared with vector control. Ribosomal protein S6, an important downstream target of AKT and mTOR, exhibited a similar phosphorylation pattern to AKT Ser473 (Fig. 3B ).
Discussion
To our knowledge, this is the first report of somatic PIK3R1 (p85a) mutations in endometrial carcinoma. The high frequency and nonrandom distribution of these mutations strongly suggests that mutations of PIK3R1 may be examples of "driver" mutations (16) that confer a selective advantage in endometrial tumorigenesis. In support of this idea, we show that stable expression of several p85a mutants leads to functional activation of the PI3K pathway, as evidenced by increased phosphorylation of AKT Ser473 . Our present findings have relevance not only to endometrial cancer but also to other tumor types; one of the mutants (p85adelH450-E451) that we have shown to promote AKT Ser473 phosphorylation has also been found in a glioblastoma (14) .
Analysis of 2 in-frame deletion mutants that correspond to the 2 shortest regions of overlapping deletion within the proximal p85a-iSH2 domain (p85adelK459 and p85adelY463-L466) showed that each promotes phosphorylation on AKT Ser473 . On the basis of this finding, we predict that the additional overlapping in-frame deletions are also likely to have altered biochemical properties. Although we have not determined the mechanism by which these deletions promote AKT phosphorylation, we speculate that it might result from 1 732 altered interactions between the mutant forms of p85a and the cell membrane, as structural studies have suggested that residues 447 to 561 of p85a form contact with lipid membranes (17) and/or from altered interactions between the p85a-iSH2 domain and the p110a-ABD domain (18) .
An excess of p85a-nSH2 and -iSH2 truncation mutants was observed in endometrial tumors that had coexisting mutations in PIK3CA. We therefore hypothesize that these truncating mutants of p85a are not functionally equivalent to p110a mutants. In support of this idea, the p85aR348X and Tumor   T132  T134  T88  T122  T100  T130  T106  T119  T104  T126  T124  T129  T93  T95  T120  T137  T128  T85  T99  T121  T92  T117  T131  T96  T116  T103  T115  T123  T133  T118  T97  T89  T94  T101  T102  T87  T125  T127  T91  T105  T84  T90   T3  T61  T74  T79  T77  T113  T21  T28  T68  T10  T29  T41  T49  T53  T59  T63  T69  T71  T75  T76  T80  T81  T82  T78  T108  T19  T46  T8  T17  T22  T23  T25  T26  T27  T30  T31  T32  T33  T34  T42  T43  T44  T45  T47  T48  T50  T52  T54  T55  T58  T60  T62  T64  T65  T66  T67  T70  T83  T110  T107  T112  T114  T109  T51 p85aK511VfsX2 truncations, which coexist with p110a mutations, did not bind to p110a or increase p-AKT Ser473 levels when stably expressed in U2OS cells. In the case of the p85aR348X mutant, this is consistent with previous observations that this protein fails to bind p110a (10) . Because the p85aR301X and p85aY334X mutants, which also coexisted with p110a mutations, truncate p85a amino terminal to residue 348, we predict that these mutants also do not bind p110a or hyperphosphorylate AKT. Exactly how the truncating mutants of p85a, which coexist with p110a mutants, affect p85a function remains to be determined. Nonetheless, their effect on structurally important domains, their preferential co-occurrence with p110a mutations, and the recurrent nature of the R348X mutant here and in colorectal cancers (10) strongly suggest that these are likely to be driver mutations that contribute to endometrial tumorigenesis. Because the majority of somatic PIK3R1 mutations uncovered in NEECs were truncation mutants, of uncertain functional significance, future studies will be critical to elucidate the contribution of p85a disruption to this tumor subtype.
In conclusion, we have identified a new mode of PI3K alteration in primary endometrial tumors. Targeted therapies directed against the PI3K pathway have already entered clinical trials for patients with endometrial cancer (19) (20) (21) . Our findings indicate that it will be important to consider the mutational status of PIK3R1 as molecular correlates associated with clinical outcome are sought. Finally, given our observation that not all p85a mutants are functionally equivalent, future studies will be critical to understand the biochemical properties of the complete spectrum of PIK3R1 mutations present in endometrial carcinoma.
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